MedTrace Logo

Study Developed to Evaluate the Effect of ANG-3777 on QT/QTc Interval

NCT04898907 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2021-06-01

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effect of ANG-3777 on placebo-corrected change from baseline, QT/corrected QT (QTc) interval, following single intravenous (IV) doses in healthy volunteer adults.

Conditions

  • Healthy Volunteer

Interventions

DRUG

ANG-3777 (Therapeutic Dose)

Arms assigned to this intervention will receive 2 mg/kg, IV, Fasted

DRUG

ANG-3777 (Supra-therapeutic Dose)

Arms assigned to this intervention will receive 6 mg/kg, IV, Fasted

DRUG

Placebo

Arms assigned to this intervention will receive normal saline, IV, Fasted

DRUG

Moxifloxacin Hydrochloride

Arms assigned to this intervention will receive 400 mg, Oral, Fasted

Sponsors & Collaborators

  • Quotient Sciences

    collaborator INDUSTRY

  • Angion Biomedica Corp

    lead INDUSTRY

Principal Investigators

  • Jeffrey Levy, MD, PhD · Quotient Sciences - Miami, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-30
Primary Completion
2021-09-30
Completion
2021-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04898907 on ClinicalTrials.gov